MedPath

MICHAEL BURKE

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Blinatumomab Bridging Therapy for BALL

Phase 2
Terminated
Conditions
B-cell Acute Lymphoblastic Leukemia
Relapsed B-cell Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2020-09-21
Last Posted Date
2025-05-13
Lead Sponsor
Michael Burke
Target Recruit Count
2
Registration Number
NCT04556084
Locations
🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Epigenetic Reprogramming in Relapse AML

First Posted Date
2015-04-09
Last Posted Date
2019-01-24
Lead Sponsor
Michael Burke
Target Recruit Count
3
Registration Number
NCT02412475
Locations
🇺🇸

Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.